No Data
No Data
Senti Biosciences Reports Addl Positive Preliminary Data From Phase 1 Clinical Trial Of SENTI-202 For Treatment Of R/R Hematologic Malignancies Including AML
Top Midday Decliners
Senti Biosciences Pauses Enrollment in Hepatocellular Carcinoma Trial in China; Shares Fall
Senti Biosciences Unveils Promising Phase 1 Trial Data
Trending Stocks Today | INNEOVA Holdings Soars 93.06% Pre-Market
Express News | Senti Bio’s Senti-202, a First-in-Class off-the-Shelf Logic Gated Selective Cd33 or Flt3 Not Emcn Car Nk Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients With Relapsed/Refractory Aml